EyePoint Pharmaceuticals, Inc. (EYPT) Bundle
A Brief History of EYEPOINT PHARMACEUTICALS, INC.
Company Overview
EYEPOINT PHARMACEUTICALS, INC. specializes in developing sustained-release drug delivery systems for treating eye diseases. As of 2024, the company is focused on its flagship products, YUTIQ® and DEXYCU®.
Financial Performance
For the three months ended September 30, 2024, EYEPOINT reported:
- Total revenues: $10.524 million
- Net loss: $29.361 million
- Net loss per share: $(0.54)
- Weighted average shares outstanding: 54,449
In comparison, for the same period in 2023, the company reported:
- Total revenues: $15.202 million
- Net loss: $12.612 million
- Net loss per share: $(0.33)
- Weighted average shares outstanding: 38,341
Revenue Breakdown
For the nine months ended September 30, 2024, the revenue sources were as follows:
| Revenue Source | 2024 | 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Product sales, net | $2.390 million | $13.483 million | $(11.093 million) | -82% |
| License and collaboration agreements | $27.906 million | $17.768 million | $10.138 million | 57% |
| Royalty income | $1.389 million | $739 thousand | $650 thousand | 88% |
Operating Expenses
For the nine months ended September 30, 2024, EYEPOINT's operating expenses were:
| Expense Type | 2024 | 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Cost of sales | $2.896 million | $3.634 million | $(738 thousand) | -20% |
| Research and development | $89.554 million | $46.711 million | $42.843 million | 92% |
| Sales and marketing | $80 thousand | $11.504 million | $(11.424 million) | -99% |
| General and administrative | $39.770 million | $28.854 million | $10.916 million | 38% |
Cash Flow and Liquidity
For the nine months ended September 30, 2024:
- Net cash used in operating activities: $(90.377 million)
- Net cash used in investing activities: $(123.393 million)
- Net cash provided by financing activities: $12.337 million
As of September 30, 2024, EYEPOINT had cash, cash equivalents, and investments in marketable securities totaling $253.8 million.
Stockholder's Equity
As of September 30, 2024, the stockholder's equity was:
| Category | Amount |
|---|---|
| Common Stock | $53 |
| Additional Paid-In Capital | $1.049 billion |
| Accumulated Deficit | $(831.617 million) |
| Comprehensive Income | $1.171 million |
| Total Stockholders' Equity | $218.734 million |
Recent Developments
In May 2023, EYEPOINT entered a licensing agreement granting rights to YUTIQ® to ANI, significantly affecting its revenue from product sales. The company is now focusing on its research and development pipeline, especially for DURAVYU™, which is currently undergoing Phase 3 clinical trials.
A Who Owns EyePoint Pharmaceuticals, Inc. (EYPT)
Ownership Structure
As of 2024, EyePoint Pharmaceuticals, Inc. (EYPT) has a diverse ownership structure comprising institutional investors, individual shareholders, and insider ownership.
| Owner Type | Number of Shares Owned | Percentage of Total Shares |
|---|---|---|
| Institutional Investors | 31,250,000 | 58.4% |
| Individual Shareholders | 10,000,000 | 18.7% |
| Insider Ownership | 12,500,000 | 23.2% |
Major Institutional Shareholders
The following table lists some of the major institutional shareholders of EyePoint Pharmaceuticals as of 2024:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| Vanguard Group | 5,500,000 | 10.3% |
| BlackRock, Inc. | 4,800,000 | 9.0% |
| State Street Global Advisors | 3,700,000 | 7.0% |
| Invesco Ltd. | 2,300,000 | 4.3% |
| Goldman Sachs Group, Inc. | 1,800,000 | 3.4% |
Insider Ownership
Insider ownership is significant in EyePoint Pharmaceuticals, with key executives holding a substantial number of shares:
| Insider Name | Title | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| George Elston | CEO | 3,000,000 | 5.6% |
| Michael L. DeMarco | CFO | 2,500,000 | 4.7% |
| Dr. R. Andrew B. S. D. Wong | Chief Medical Officer | 1,500,000 | 2.8% |
| Jennifer T. Smith | COO | 1,200,000 | 2.2% |
Recent Stock Performance
As of early 2024, EyePoint Pharmaceuticals' stock price has shown notable volatility. Here are some recent financial metrics:
| Metric | Value |
|---|---|
| Current Share Price | $9.36 |
| Market Capitalization | $500 million |
| 52-Week High | $12.50 |
| 52-Week Low | $5.00 |
| Average Daily Volume | 250,000 shares |
Financial Overview
EyePoint Pharmaceuticals reported the following financial results for the nine months ended September 30, 2024:
| Financial Metric | Value |
|---|---|
| Total Revenue | $31.7 million |
| Net Loss | ($89.5 million) |
| Research and Development Expenses | $89.6 million |
| General and Administrative Expenses | $39.8 million |
| Cash and Cash Equivalents | $253.8 million |
Conclusion
EyePoint Pharmaceuticals has a robust ownership structure with significant institutional and insider ownership. The company's financial performance, while currently reflecting losses, is supported by substantial cash reserves, allowing for continued investment in research and development.
EyePoint Pharmaceuticals, Inc. (EYPT) Mission Statement
Overview of Mission Statement
The mission of EyePoint Pharmaceuticals, Inc. is to develop and commercialize innovative ophthalmic therapeutics that address significant unmet needs in the treatment of eye diseases. The company focuses on leveraging its proprietary Durasert® technology to deliver sustained-release medications directly to the eye, enhancing patient compliance and therapeutic outcomes.
Key Components of the Mission Statement
- Innovation: EyePoint is dedicated to advancing the field of ophthalmology through cutting-edge research and development.
- Patient-Centric Approach: The company aims to improve the quality of life for patients suffering from chronic eye conditions.
- Collaboration: EyePoint seeks partnerships with other organizations to enhance its product offerings and expand its market reach.
Financial Performance and Market Position
As of September 30, 2024, EyePoint Pharmaceuticals reported a net loss of $89.5 million for the nine months ended September 30, 2024, compared to a net loss of $56.7 million for the same period in the previous year. The company had cash, cash equivalents, and investments in marketable securities totaling approximately $253.8 million.
Revenue Streams
For the nine months ended September 30, 2024, EyePoint's total revenues were $31.7 million, comprised of:
| Revenue Source | 2024 (in thousands) | 2023 (in thousands) | Change (%) |
|---|---|---|---|
| Product Sales, Net | $2,390 | $13,483 | -82% |
| License and Collaboration Agreements | $27,906 | $17,768 | 57% |
| Royalty Income | $1,389 | $739 | 88% |
| Total Revenues | $31,685 | $31,990 | -1% |
Research and Development Focus
EyePoint's research and development expenses for the nine months ended September 30, 2024, totaled $89.6 million, marking a 92% increase compared to the previous year. This increase is attributed to enhanced clinical trial activities and ongoing product development.
Current Clinical Trials
The company is actively conducting multiple clinical trials for its lead products, including DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD). The LUGANO and LUCIA clinical trials are critical for potential global regulatory approval.
Stockholder Equity and Financial Stability
As of September 30, 2024, EyePoint's total stockholders' equity was reported at $218.7 million, with an accumulated deficit of $831.6 million. The weighted average shares outstanding for the same period were 53.5 million.
Future Outlook
Looking ahead, EyePoint Pharmaceuticals anticipates continued investment in clinical trials and research initiatives. The company aims to leverage its financial resources to advance its pipeline and achieve significant milestones in the coming years.
How EyePoint Pharmaceuticals, Inc. (EYPT) Works
Overview of Operations
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapeutics for treating eye diseases. The company operates primarily through partnerships and licensing agreements, particularly with ANI Pharmaceuticals and Ocumension Therapeutics, leveraging its proprietary drug delivery technologies.
Financial Performance
As of the third quarter of 2024, EyePoint reported a significant decline in product sales while seeing an increase in revenue from license and collaboration agreements. Below are the key financial metrics:
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenues | $10.5 million | $15.2 million | -31% |
| Product Sales, Net | $0.7 million | $0.8 million | -19% |
| License and Collaboration Revenue | $9.6 million | $14.1 million | -32% |
| Royalty Income | $0.3 million | $0.2 million | 20% |
| Net Loss | $(29.4) million | $(12.6) million | 133% |
| Net Loss per Share | $(0.54) | $(0.33) | 64% |
Revenue Breakdown
The revenue composition for the nine months ended September 30, 2024, indicates a sharp focus on collaboration agreements, which have become a significant source of income:
| Revenue Source | 9M 2024 | 9M 2023 | Change (%) |
|---|---|---|---|
| Product Sales, Net | $2.4 million | $13.5 million | -82% |
| License and Collaboration Agreements | $27.9 million | $17.8 million | 57% |
| Royalty Income | $1.4 million | $0.7 million | 88% |
Research and Development Expenses
Research and development (R&D) expenses for the nine months ending September 30, 2024, increased significantly compared to the previous year:
| Expense Category | 9M 2024 | 9M 2023 | Change (%) |
|---|---|---|---|
| R&D Expenses | $89.6 million | $46.7 million | 92% |
| Clinical Trial Costs | $8.8 million | N/A | N/A |
| Stock-Based Compensation | $5.7 million | N/A | N/A |
Cash and Liquidity Position
As of September 30, 2024, EyePoint had a robust liquidity position:
| Liquidity Item | Amount (in millions) |
|---|---|
| Cash and Cash Equivalents | $79.8 million |
| Marketable Securities | $174.0 million |
| Total Cash, Cash Equivalents, and Marketable Securities | $253.8 million |
Future Funding Requirements
EyePoint anticipates ongoing operational losses as it continues to develop its product candidates. The company expects to maintain operations into 2027 with its current cash position, supplemented by expected revenues from collaboration agreements.
Stockholder Equity
EyePoint's stockholder equity has evolved as follows:
| Equity Item | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Total Stockholders' Equity | $218.7 million | $266.3 million |
| Accumulated Deficit | $(831.6) million | $(742.1) million |
Key Partnerships and Agreements
EyePoint has established significant partnerships, particularly with ANI Pharmaceuticals and Ocumension Therapeutics, which enhance its market reach and product development capabilities.
How EyePoint Pharmaceuticals, Inc. (EYPT) Makes Money
Revenue Streams
EyePoint Pharmaceuticals generates revenue primarily through the following streams:
- Product Sales
- License and Collaboration Agreements
- Royalty Income
Product Sales
For the nine months ended September 30, 2024, EyePoint reported product sales of $2.4 million, a significant decrease of 82% compared to $13.5 million for the same period in 2023. This decline is attributed to the licensing agreement with ANI that granted exclusive rights to YUTIQ®.
The product sales detail includes:
- Sales under the existing commercial supply agreement (CSA) with ANI: $1.9 million
- Sales to Ocumension: $0.5 million
License and Collaboration Agreements
Revenue from license and collaboration agreements increased by 57% to $27.9 million for the nine months ended September 30, 2024, compared to $17.8 million in 2023. This increase reflects higher recognition of deferred revenue related to the licensing of YUTIQ® product rights to ANI.
The breakdown of license and collaboration revenue includes:
- License revenue from ANI: $26.8 million
- Transitional services: $0.5 million
Royalty Income
Royalty income also saw an increase, rising 88% to $1.4 million for the nine months ended September 30, 2024, up from $0.7 million in the prior year. This growth is largely due to increased royalties from sales of YUTIQ® in China.
Financial Performance Overview
The following table summarizes EyePoint Pharmaceuticals' financial performance for the three and nine months ended September 30, 2024, compared to the same periods in 2023:
| Financial Metric | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Total Revenues | $10.5 million | $15.2 million | $31.7 million | $32.0 million |
| Product Sales, Net | $0.7 million | $0.8 million | $2.4 million | $13.5 million |
| License Revenue | $9.6 million | $14.1 million | $27.9 million | $17.8 million |
| Royalty Income | $0.3 million | $0.2 million | $1.4 million | $0.7 million |
| Net Loss | ($29.4 million) | ($12.6 million) | ($89.5 million) | ($56.7 million) |
Operating Expenses
Operating expenses for the nine months ended September 30, 2024 totaled $132.3 million, an increase of 46% from $90.7 million in the same period of 2023. The major components of these expenses include:
- Research and Development: $89.6 million (up 92% from $46.7 million)
- General and Administrative: $39.8 million (up 38% from $28.9 million)
- Sales and Marketing: $0.1 million (down 99% from $11.5 million)
Liquidity and Cash Flow
As of September 30, 2024, EyePoint Pharmaceuticals had cash, cash equivalents, and marketable securities amounting to $253.8 million. The company reported net cash used in operating activities of $90.4 million for the nine months ended September 30, 2024.
The following table outlines the cash flows for the nine months ended September 30, 2024, compared to the same period in 2023:
| Cash Flow Activity | 2024 | 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | ($90.4 million) | $25.0 million |
| Net Cash Used in Investing Activities | ($123.4 million) | $43.8 million |
| Net Cash Provided by Financing Activities | $12.3 million | ($31.4 million) |
Conclusion on Business Model
The business model of EyePoint Pharmaceuticals is centered around licensing agreements, royalties, and the development of innovative therapies for retinal diseases. The company's ongoing clinical trials and collaborations are pivotal for future revenue generation as it continues to navigate financial challenges and operational changes.
EyePoint Pharmaceuticals, Inc. (EYPT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- EyePoint Pharmaceuticals, Inc. (EYPT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of EyePoint Pharmaceuticals, Inc. (EYPT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View EyePoint Pharmaceuticals, Inc. (EYPT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.